Metagenomi Therapeutics (MGX) Gains from Investment Securities (2023 - 2026)
Metagenomi Therapeutics (MGX) reported Gains from Investment Securities of $60850.0 for Q1 2026, down 43.7% year-over-year from $108089.0 in Q1 2025, and down 97.29% quarter-over-quarter from $2.2 million in Q4 2025.
Metagenomi Therapeutics (MGX) Gains from Investment Securities (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has 4 years of Gains from Investment Securities data on file, last reported at $60850.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $60850.0, down 43.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $60850.0 (down 43.7% YoY), and the FY2025 annual result was $2.2 million, up 3410.36% from the prior year.
- Gains from Investment Securities declined to $60850.0 in Q1 2026 per MGX's latest filing, from $2.2 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $30.6 million in Q1 2023 and troughed at $60850.0 in Q1 2026.
- A 4-year average of $3.3 million and a median of $108089.0 in 2025 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities plunged 99.79% in 2024, then jumped 3410.36% in 2025.
- A 4-year view of Gains from Investment Securities shows it stood at $228000.0 in 2023, then tumbled by 71.96% to $63940.0 in 2024, then jumped by 3410.36% to $2.2 million in 2025, then sank by 97.29% to $60850.0 in 2026.
- Business Quant data shows MGX's Gains from Investment Securities at $60850.0 in Q1 2026, $2.2 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - |
| 10 | Metagenomi Therapeutics | 42.84 Mn | 42.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60,850.00 |
| Mar 31, 2026 | 60,850.00 |
| Dec 31, 2025 | 2.24 Mn |
| Dec 31, 2025 | 2.24 Mn |
| Sep 30, 2025 | 1.34 Mn |
| Sep 30, 2025 | 1.34 Mn |
| Jun 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | 108,089.00 |
| Mar 31, 2025 | 108,089.00 |
| Dec 31, 2024 | 63,940.00 |
| Dec 31, 2024 | 63,940.00 |
| Sep 30, 2024 | 63,940.00 |
| Sep 30, 2024 | 63,940.00 |
| Jun 30, 2024 | 63,940.00 |
| Jun 30, 2024 | 63,940.00 |
| Mar 31, 2024 | 63,940.00 |
| Mar 31, 2024 | 63,940.00 |
| Dec 31, 2023 | 228,000.00 |
| Dec 31, 2023 | 228,000.00 |